Impact of individual characteristics of an organism, pathological processes, and combined administration of medicinal products on their efficacy

September 6, 2018
728
Resume

The causes for the decrease (absence) of effectiveness of medicinal products are analyzed: genetically determined characteristics of a patient, effects of comorbid pathological processes, consequences of drug interaction in their combined use, their interaction with food products, effects of smoking, infectious agents’ resistance to antimicrobial drugs.

Published: 05.09.2018

References:

  • Archakov A.I. (1983) Oksigenazyi biologicheskih membran. 37-e Bahovskoe chtenie. Nauka, Moskva, 56 s.
  • Bazhora Yu.I. (2003) Farmakohenetyka: dosiahnennia i perspektyvy. Druk, Odesa, 140 s.
  • Baryisheva V.O., Ketova G.G. (2016) Personalizirovannaya meditsina: realizatsiya farmakogenetiki v praktike. Nepreryivnoe meditsinskoe obrazovanie i nauka, 11(1): 4–7.
  • Belousov Yu.B., Gurevich K.G. (2005) Klinicheskaya farmakokinetika. Praktika dozirovaniya lekarstv: Spets. vyipusk serii «Ratsionalnaya farmakoterapiya». Litterra, Moskva, 288 s.
  • Bobrova O.P., Shnayder N.A., Zyiryanov S.K. (2017) Molekulyarnaya diagnostika polimorfizma genov biotransformatsii opioidnyih analgetikov i ee rol v izuchenii modifikatsionnoy izmenchivosti obezbolivaniya v klinicheskoy onkologii. V kn.: Molekulyarnaya dIagnostika, T. 1. Farmakogenetika i farmakogenomika, s. 519–520.
  • Volovikova O.N., Mihaylova E.I. (2012) Rol farmakogenetiki v razvitii personalizirovannoy meditsinyi pri zabolevaniyah vnutrennih organov (obzor literaturyi). Problemyi zdorovya i ekologii, 2(32): 13–18.
  • Drogovoz S.M., Gudzenko A.P., Butko Ya.A., Drogovoz V.V. (2010) Pobochnoe deystvie lekarstv: Uchebnik-spravochnik. SIM, Harkov, 480 s.
  • Zhuravleva M.V., Kukes V.G., Prokofev A.B. i dr. (2015) Effektivnost i bezopasnost primeneniya lekarstvennyih sredstv: znachenie i vozmozhnosti klinicheskoy farmakologii. Vedomosti Nauchnogo tsentra ekspertizyi sredstv meditsinskogo primeneniya, 2: 20–24.
  • Meditsinskoe informatsionnoe agentstvo, Moskva, 656 s.
  • Ivanov A.M., Kamilova T.A., Dovgopolyuk A.B., Abritalin E.Yu. (2010a) Farmakogenetika v psihiatrii: antidepressantyi. Vest. Ros. voen.-med. akad., 2: 201–210.
  • Ivanov A.M., Kamilova T.A., Dovgopolyuk A.B., Abritalin E.Yu. (2010b) Farmakogenetika v psihiatrii: neyroleptiki. Ros. voen.-med. akad., 3: 238–245.
  • Komarov A.L. (2015) Otsenka chuvstvitelnosti k klopidogrelu: sovremennoe sostoyanie problemyi. Aterotromboz, 2: 95–106.
  • Korzhov V.I., Zhadan V.N., Korzhov M.V. (2007) Rol sistemyi glutationa v protsessah detoksikatsii i antioksidantnoy zaschityi. Zhurn. AMN UkraYini, 13(1): 3–19.
  • Kravchenko I.A. (2005) Farmakohenomika z osnovamy farmakohenetyky: Navch. pos. Astroprynt, Odesa, 144 s.
  • Lazoryshynets V.V., Khobzei M.K., Mariievskyi V.F. ta in. (2011) Antybiotykorezystentnist klinichnykh shtamiv Enterobacter spp. v khirurhichnykh statsionarakh Ukraini v 2010 r. Liky Ukrainy, 1(5): 34–38.
  • Mariievskyi V.F., Salmanov A.H., Khobzei N.K., Zozulia Y.S. (2011) Antybiotykorezystentnist klinichnykh shtamiv Enterococcus faecalis u khirurhichnykh statsionarakh Ukrainy v 2010r. Ukr. med. chasop., 3(83): 119–122.
  • Matvieieva O., Yaichenia V. (2014) Otsutstvye эffektyvnosty lekarstvennoho sredstva yly medytsynskaia oshybka? Medychna hazeta Ukrainy «Vashe zdorovia», s. 7–8.
  • Maharin O.A., Maklyakov Yu.S., Zhenilo V.M. (2012) Polimorfizm genov sistemyi detoksikatsii ksenobiotikov i ego rol v biotransformatsii vnutrivennyih anestetikov. Biomeditsina, 1(1–3): 98–107.
  • Melnik A.A. (2016) Primenenie farmakogenotipirovaniya i dozirovanie nekotoryih preparatov v urologii i nefrologii. Pochki, 1(15): 96–104.
  • Panchyshyn Yu..M., Yakubenko Yu.P. (2011) Statyny: pliusy ta minusy. Rats. farmakoter., 1(18): 47–56.
  • Posokhova K.A. (2017) Yak kharchuvatysia pry likuvanni varfarynom. farmakoter., 2(43): 12–17.
  • Renki P.Dzh., Renki R.G., Dzhon E., Renki G.N. (2014) Vliyanie upakovki na stabilnost lekarstvennyih preparatov. tehnol. upak., 6(244): 62–65.
  • Sadvakas A.S. (2014) Рharmacogenetics of drug transporters. Nauka 21 veka: voprosyi, gipotezyi, otvetyi, 4: 55–60.
  • Salmanov A.H. (2015) Antymikrobna rezystentnist ta infektsii, asotsiiovani z medychnoiu dopomohoiu v Ukraini. Epidemiolohichnyi zvit multytsentrovoho doslidzhennia (2010–2014 rr.). Ahshrar Media hrup, Kyiv, 452 s.
  • Samura B.A. (red.) (2009) Zahalna farmakokinetyka. TDMU, Ternopil, 356 s.
  • Sidorenko I.A., Galaeva Ya.Yu., Naletov S.V., Konyisheva N.V. (2017) Farmakogenetika i farmakoterapiya: obschie voprosyi. Un-tetskaya klinika, 12(1): 89–93.
  • Skakun N.P. (1981) Klinicheskaya farmakogenetika. Zdorovia, Kyiv, 200 s.
  • Skakun N.P., Saratikov A.S., Oleynik A.N., Vengerovskiy A.I. (1985) Etilovyiy alkogol (farmakokinetika, vzaimodeystvie s lekarstvami, gepatotoksichnost). Izd-vo Tomsk. un-ta, Tomsk, 135 s.
  • Syichev D.A., Ignatev I.V., Emelyanov N.V. i dr. (2009) Farmakogeneticheskoe testirovanie: pervyie shagi v realnoy klinicheskoy praktike i problemyi standartizatsii. Problemyi standartizatsii v zdravoohranenii, 1: 43–55.
  • Tashenova A.I. (2010) Transportnaya sistema glikoproteina-R i farmakokinetika lekarstvennyih sredstv. Biomeditsina, 1(4): 24–32.
  • Feshchenko Yu.I., Humeniuk M.I., Denysov O.S. (2010) Antybiotykorezystentnist mikroorhanizmiv. Stan problemy ta shliakhy yii vyrishennia. Ukr. khimioter. zhurn., 23(1–2): 4–10.
  • Chekman I.S., Posohova E.A., Beregovaya E.G. (1996) Mikrosomalnaya fermentnaya sistema organizma. Kiev–Zaporozhe, 80 s.
  • Yakovleva O.O., Konovalova N.V., Kosovan A.I. ta in. (2011) Klinichna farmakohenetyka: Navch. posib. Nova knyha, Vinnytsia, 160 s.
  • Cambria-Kiely J.A. (2002) Effect of soy milk on warfarin efficacy. Ann. Pharmacother., 36(12): 1893–1896.
  • Ede M.C.M. (1973) Circadian rhythms of drug effectiveness and toxicity. Clin. Pharm. Therap., 14(6): 925–935.
  • Food and Drug Administration US (2016) Table of pharmacogenomic biomarkers in drug labeling [2015-07-29].
  • http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm 083378. htm
  • Hider S.L., Bruce I.N., Thomson W. (2007) The pharmacogenetics of methotrexate. Rheumatology, 46(10): 1520–1524.
  • Karlson B., Leijd B., Hellström K. (1986) On the influence of vitamin K‐rich vegetables and wine on the effectiveness of warfarin treatment. J. Inter. Med., 220(4): 347–350.
  • Kempin S.J. (1983) Warfarin resistance caused by broccoli. New Engl. J. Med., 308(20): 1229–1230.
  • Lee M., Schwartz R.N., Sharifi R. (1981) Warfarin resistance and vitamin K. Ann. Inter. Med., 94(1): 140–141.
  • Martens H.J., De Goede P.N., Van Loenen A.C. (1990) Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am. J. Health-Syst. Pharm., 47(2): 369–373.
  • Oliynyk O.V., Titov I.I., Pereviznyk B. (2016) Epidemiology of severe sepsis caused by severe craniocerebral trauma in Western Ukraine. Hospital surgery, 1(1): 44–50.
  • Pedersen F.M., Hamberg O., Hess K., Ovesen L. (1991) The effect of dietary vitamin K on warfarin‐induced anticoagulation. J. Intern. Med., 229(6): 517–520.
  • Seifi A., Mowla A., Vaziri M.M. et al. (2004) Insulin adsorbance to polyvinylchloride (PVC) surfaces of fluid container and infusion-set. Mid. East J. Anaesthesiol., 17(5): 975–981.
  • Thompson C., Vital-Carona J., Faustino E.V.S. (2012) The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. Diabet. Technol. Therapeut., 14(10): 912–916.
  • Weir S.J., Myers V.A., Bengtson K.D., Ueda C.T. (1985) Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets. Am. J. Health-Syst. Pharm., 42(12): 2679–2683.
  • World Health Organization (2001) WHO global strategy for containment of antimicrobial resistance: executive summary (WHO/CDS/CSR/DRS/2001.2).